RNAZ (TransCode Therapeutics) Momentum Rank: 5 (As of Sep. 09, 2026) — 150% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNAZ TransCode Therapeutics Inc RNAZ
32 GF Score
Price $1.83
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Momentum Rank?

TransCode Therapeutics RNAZ -5.67% 32 Momentum Rank is 5 as of Sep. 09, 2026, which is 150% above its 10-year median of 2.00. GuruFocus rates RNAZ with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

TransCode Therapeutics has the Momentum Rank of 5.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

TransCode Therapeutics Momentum Rank Related Terms

RNAZ vs VRAX, OGEN, ONCO: Momentum Rank Comparison

For the Biotechnology subindustry, TransCode Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransCode Therapeutics Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where TransCode Therapeutics's Momentum Rank falls into.


RNAZ
32GF Score
TransCode Therapeutics Inc RNAZ
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 5 mean?
TransCode Therapeutics (RNAZ) has a Momentum Rank of 5 as of Sep. 09, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on TransCode Therapeutics and its competitors. This is 150% above median its historical median of 2.00. Over the past decade, TransCode Therapeutics' Momentum Rank has ranged from 1.00 to 7.00.
Is TransCode Therapeutics' Momentum Rank too high?
TransCode Therapeutics' current Momentum Rank of 5 is 150% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. Overall, TransCode Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Momentum Rank compare to VRAX and OGEN?
TransCode Therapeutics' Momentum Rank of 5 can be compared against companies in the Biotechnology industry. Historically, TransCode Therapeutics' own Momentum Rank has ranged from 1.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on TransCode Therapeutics and its competitors. TransCode Therapeutics's current Momentum Rank is 5, which is 150% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Momentum Rank of 5. The current Momentum Rank is 5, which is 150% above median its 10-year median of 2.00. TransCode Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Momentum Rank is 5 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
32GF Score

Get the complete analysis for RNAZ

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.83
Price